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A simple, sensitive, rapid and highly efficient LC-MS/MS method was developed for the determination 
of Candesartan and Hydrochlorothiazide simultaneously in human plasma. The method employed Zorbax 
eclipse C18 (150 X 4.6 mm, 5µ) column using acetate buffer: acetonitrile (25:75%, v/v) as the mobile 
phase. The mobile phase flow rate is 1 mL/min which was delivered into the mass spectrometer electron 
spray ionization chamber. The Liquid/liquid extraction procedure was used in the method for the extraction 
of analytes. The chromatograph was attached to a negative ion mode tandem mass spectrometer and the 
method was validated for all the parameters as per the guidelines of US-FDA. The ions were detected 
in multiple reaction monitoring mode and the transitions are m/z 439.00→309.10 and 295.80→268.80 
for candesartan and hydrochlorothiazide respectively. Isotopic standards were used as internal standards 
for effective recovery of the analytes. The drugs were analyzed over a calibration range of 1.027-302.047 
ng/mL for candesartan and 1.044-306.945 ng/mL for hydrochlorothiazide respectively with regression 
coefficient greater than 0.99. The mean extraction recoveries are 96.95±5.61 and 100.55±4.82 for 
candesartan and hydrochlorothiazide respectively. The precision and accuracy values for all the studies 
were within the range of ≤15% and 85-115%. The performed stability studies indicate that the developed 
method is stable in plasma for 15 h at room temperature (bench top); 52 h (in injector); for 112 days at 
-70 ºC for long term stability; five successive freeze and thaw cycles. The developed method could be 
successfully employed for the determination of selected drugs in biological samples.
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INTRODUCTION 
Candesartan (CAN), is chemically 2-ethoxy-1-
({4-[2-(2H-1, 2, 3, 4-tetrazol-5-yl) phenyl] phenyl} 
methyl)-)-1H-1,3-benzodiazole-7-carboxylic acid. It is 
an angiotensin receptor blocking agent which can be used 
alone or in combination with other drugs for the treatment 
of hypertension. It competes with angiotensin-II for its 
receptors there by lowering blood pressure. It is also used 
as an effective alternative for the treatment of heart failure, 
myocardial infarction, coronary diseases and systolic 
dysfunction (The Merck Index, 2006).
Hydrochlorothiazide (HCT), is chemically 
6-chloro-1, 1-dioxo-3, 4-dihydro-2H-1,2,4-benzo-
thiadiazine-7-sulfonamide. It is a prototypical member of 
the thiazide diuretic. It helps in reduction of reabsorption 
of various electrolytes through renal tubules resulting 
in excretion of water along with different electrolytes 
like sodium, potassium, chloride, magnesium etc. It is 
widely used in the treatment of edema, hypertension, 
hyperparathyroidism, and diabetes insipidus (The Merck 
index, 2006).
Thorough survey of literature disclosed good 
number of analytical methods which include UV (Erk, 
2003a; Naseemet al., 2009), HPTLC (Bipin, Sachinet al., 
2008), HPLC (Qutab et al., 2007; Be et al., 1990; Richter, 
Oertel, Kir, 1996; Erk, 2003b; Zendelovska, Stafilovm 
Molisevski, 2004; Balamuralikrishna, Syamasundar, 
2010; Annapurna, Narendra, Ravi, 2012; Veeranjaneyulu, 
Aneesha, Nandakishore, 2012; Narendra, Satyanarayana, 
Ganga, 2012), LC-MS (Brushinina et al., 2014; Surbhi et 
al., 2010; Bharathi et al., 2012) and UPLC-MS (Singh 
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et al., 2014) methods are available for the evaluation of 
CAN and HCT in bulk, pharmaceutical dosage forms and 
in biological samples individually or in combination with 
other drugs. To our knowledge, no LC-MS/MS method is 
available for the simultaneous evaluation of these drugs 
in human plasma using isotopic internal standards. Hence, 
we made an attempt to develop a simple method for the 
appraisal of these drugs. The developed method has been 
validated as per the guidelines given by US-FDA for 
biological samples (ICH, 1996; ICH, 1997).
EXPERIMENTAL
Chemicals and materials 
CAN and HCT were procured from Dr. Reddy’s 
Laboratories Limited, Hyderabad, India. Candesartan 
d4 (CAN- IS), Hydrochlorothiazide 13C6 (HCT-IS) were 
obtained from Clear-synth Labs Limited, Mumbai, 
India. HPLC grade methanol, HPLC grade acetonitrile, 
analytical grade formic acid and HPLC grade diethyl ether 
were purchased from Merck Specialties, Mumbai, India. 
K2EDTA human plasma was obtained from a registered 
blood bank, Secunderabad, India and was stored at –20°C 
prior to use.
Liquid chromatographic and mass spectrometry 
A Shimadzu HT (Shimadzu, Japan) LC system 
which was furnished with degasser (DGU-20A5), binary 
pump (LC-20AD) in company with auto-sampler (SIL-
HTC) was used. Zorbax Eclipse C18 (150 × 4.6 mm, 5 
µm) column was employed for the separation of analytes, 
which was preserved at 40°C±2°C in column oven (CTO-
10AS). A mixture of 5 mM ammonium acetate: acetonitrile 
(25:75%, v/v) was filtered as mobile phase, which was 
delivered at a flow rate of 1.0 mL/min into the mass 
spectrometer electrospray ionization chamber. 
Analytes and IS were ascertained by MS/MS 
detection under negative ion mode using an MDS Sciex 
(Foster City, CA, USA) API-4000 mass spectrometer. It is 
furnished with a Turbo ion spray. The routine specifications 
like curtain gas, nebulizer gas (GS1), auxiliary gas (GS2) 
and collision gas (CAD) were fixed at 20, 21, 31 and 
6 psi, respectively. The compounds specifications like 
declustering potential (DP), collision energy (CE), collision 
exit potential (CEP) and entrance potential (EP) for CAN, 
HCT, CAN-IS and HCT-IS were -40, -30, -15, -10 V; -99, 
-29, -15, -10 V ; -40, -32, -15, -10 V and -99, -29, -15, -10 
V respectively. Diagnosis of the ions was accomplished in 
the multiple reaction monitoring (MRM) mode, observing 
the transition of the m/z 439.00 parent ion to the m/z 309.10 
daughter ion for CAN, m/z 295.80 parent ion to the m/z 
268.80 daughter ion for HCT, m/z 443.00 parent ion to the 
m/z 312 00 daughter ion for CAN-IS and m/z 301.80 parent 
ion to the m/z 274.90 daughter ion for HCT-IS. The dwell 
time was 200 msec. The analytical data were exercised by 
Analyst software (version 1.4.2). Summary of optimized 
method parameters were tabulated in Table I and optimized 
system parameters were portrayed inTable II.
TABLE I - Summary of optimized conditions
Parameter Condition
Column Zorbax Eclipse XDB-C18 4.6 x 150 mm, 5 µm (Make: Agilent Technologies)
Mobile phase HPLC grade acetonitrile:5 mM ammonium acetate in water(75:25, v/v)
Rinsing solution HPLC grade acetonitrile:milli-Q water or HPLC grade water (60:40, v/v)
Flow rate 1.0 mL/minute (with splitter)
Split ratio 50:50
Sample cooler temperature 10°C
Injection volume 15 µL
Needle rinsing volume 500 µL
Column oven temperature N/AP
Rinsing mode Before and after aspiration
Retention time Candesartan 1.10±0.1 minutes
Candesartan d4 1.10±0.1 minutes
Hydrochlorothiazide 1.40±0.1 minutes
Hydrochlorothiazide 13C6 1.40±0.1 minutes
Run time 3.00 minutes
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Preparation of reagents
5 mM ammonium acetate buffer
About 385.4 mg of ammonium acetate was weighed 
accurately and transferred into a clean and dry 1000 mL 
standrad flask. About 100 mL of HPLC/Milli Q grade 
water was added to mix the contents and then subjected 
to sonication on an ultrasonicator for 5 min. Finally, the 
solution was made up to the mark with HPLC/Milli Q 
grade water.
Mobile phase (25:75%, v/v) 
500 mL of 5mM ammonium acetate was transferred 
into a two liters volumetric flask. About 500 mL of HPLC 
grade acetonitrile was added to it and mixed it well, 
sonicated in an ultrasonic bath for 5 min and made up to 
the mark with acetonitrile.
Diluent (v/v)
A mixture of HPLC grade acetonitrile and Milli Q/
HPLC grade water in the volume ratio of 60:40%, v/v 
respectively was prepared and used as diluent. 
Rinsing Solution (v/v)
The Diluent was employed as a rinsing solution.
5% formic acid buffer(v/v)
5.00 mL of formic acid was carefully withdrawn 
using calibrated pipette and transferred into a 100 mL 
standard flask and to this few mL of Milli Q/HPLC 
grade water was added and mixed it well, then sonicated 
it in an ultrasonic bath for 5 min, finally made up to 
the mark.
Preparation of internal standards (IS) solution
Accurately weighed and transferred 2 mg of 
Candesartan d4 and Hydrochlorothiazide 
13C6 working 
standards separately into 2 mL standard flasks. Dissolved 
in HPLC grade methanol and made up the volume with 
the same to produce a solution of 1.0000 mg/mL of 
candesartan d4 and hydrochlorothiazide 13C6. 
Combined stock dilution of candesartan d4 and 
hydrochlorothiazide 13C6 was prepared at a concentration 
of 5000.000 ng/mL and 5000.000 ng/mL, respectively 
using diluent.
Preparation of candesartan and hydrochlorothiazide 
stock solution
Accurately weighed and transferred 2 mg of 
candesartan and hydrochlorothiazide working standards 
separately into 2 mL volumetric flasks. Dissolved in HPLC 
grade methanol and made up the volume with the same to 
produce a solution of 1.0000 mg/mL of candesartan and 
hydrochlorothiazide.
Sample preparation 
One set of calibration curve standards; one or more 
sets of quality control samples and plasma samples were 
withdrawn from the deep freezer and allowed it to thaw 
at room temperature. The thawed samples were placed on 
TABLE II - LC-MS/MS optimized system parameters
Parameter CAN CAN D4 HCT HCT 13C6
Ionization mode Negative Negative Negative Negative
Detection m/z 439.00 (parent) and 
309.10 (product)
443.00 (parent) and 
312.00 (product)
295.80 (parent) and 
268.80 (product)
301.80 (parent) and 
274.90 (product)
Ion Spray Voltage (IS) -4500.00 V -4500.00 V -4500.00 V -4500.00 V
Temperature (TEM0C) 500.00 500.00 500.00 500.00
Curtain Gas (CUR) 20.00V 20.00V 20.00V 20.00V
Collision Gas (CAD) 6.00psi 6.00psi 6.00psi 6.00psi
GS1 21.00 psi 21.00 psi 21.00 psi 21.00 psi
GS2 31.00psi 31.00psi 31.00psi 31.00psi
Declustering Potential (DP) -40.00V -40.00V -99.00V -99.00V
Collision Energy (CE) -30.00 V -32.00 V -29.00 V -29.00 V
Collision Cell Exit Potential (CEP) -15.00 V -15.00 V -15.00 V -15.00 V
Entrance Potential (EP) -10.00 V -10.00 V -10.00 V -10.00 V
Dwell time (m.sec) 200 200 200 200
Software Analyst software 1.4.2
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a vortex to ensure complete mixing of the contents. 100 
µL of the sample was pipetted out into prelabelled 15 mL 
stopper glass test tubes. 10 µL of internal standard dilution 
(combined dilution of 5000.000 ng/mL Candesartan d4 
and Hydrochlorothiazide 13C6) was added, except in blank 
wherein added 10 µL of diluent and vortexed. Then, added 
500 µL of 5% formic acid buffer and vortexed. 5 mL of 
tertiary butyl methyl ether (TBME) was added and placed 
the samples for 20 min on the reciprocating shaker at 200 
rpm. Then samples were centrifuged at 4000 rpm for 10 
minutes at 4°C. Then the superficial organic layer (4 mL) 
was shifted to prelabelled glass test tubes and evaporated 
to dryness under liquid nitrogen at 45°C. The samples were 
reconstituted with 250 µL of mobile phase and 15 µL of 
the sample was injected into the system.
VALIDATION PROCEDURES 
The developed method was validated for various 
specifications to reach the acceptance criteria as per the 
guidelines of US-FDA (ICH, 1996; ICH, 1997). 
Matrix effect
The interference consequences of human plasma 
elements over the ionization of CAN, HCT, CAN-IS and 
HCT-IS were assessed in this test. The responses of the 
post extracted plasma QC samples (n=6) were equated 
with the response of analytes from neat (aqueous) standard 
samples at equivalent concentrations. It was assessed 
at low and high concentrations viz., CAN; 3.10 and 
256.20 ng/mL, HCT; 3.12 and 262.07 ng/mL, whereas 
for the internal standards it was determined at a single 
concentration of 250 ng/mL.
Specificity
The specificity of the analyte was assessed by 
concealing six different batches of human blank plasma 
spiked with its contrary analyte. 
Sensitivity
The sensitivity is determined by injecting six LLOQ 
samples from six different lots of human plasma and by 
spiking the concentration of HCT-ULOQ. The specificity 
of the HCT was determined by screening six different 
batches of human blank plasma spiked with CAN-ULOQ. 
Recovery 
The recovery of CAN, HCT, CAN-IS and HCT-IS 
was assessed by correlating the responses of the post 
extracted plasma QC standard samples (n=6) with the 
response of neat samples at equivalent concentrations. 
Calibration curve 
A nine-point calibration curve (1.027, 2.567, 5.135, 
10.27, 25.674, 51.348, 102.696, 205.392 and 302.047 ng/
mL for CAN and 1.044, 2.609, 5.219, 10.438, 26.095, 
52.189, 104.378, 208.757 and 306.995 ng/mL for HCT) 
was plotted by taking the peak area ratio of each analyte: 
internal standard against the nominal concentration of 
calibration curve standards. Using the assessment of 
different weighing factors, the results were made to fit 
by linear regression analysis with the help of 1/X2 (X: 
concentration) weighting factor. The limit for calibration 
curve is to possess a correlation coefficient (r) of 0.99 or 
more. 
Precision and accuracy 
For this study, six replicates containing CAN and 
HCT at five different QC levels were selected [for CAN: 
1.08 (LLOQ), 3.087 (LQC), 35.079 (MQC1), 152.516 
(MQC2) and 258.502 (HQC) ng/mL; for HCT: 1.092 
(LLOQ), 3.121 (LQC), 35.466 (MQC1), 154.199 (MQC2) 
and 261.354 (HQC) ng/mL]. The inter-assay precision was 
assessed by monitoring the mentioned QC level samples 
on four different runs. The benchmark for the prominence 
of the data included accuracy within ±15% deviation (SD) 
and a precision of within ±15% relative standard deviation 
(RSD) except for LLOQ, where it should not exceed ±20% 
of SD. 
Stability experiments 
The stability of analytes and internal standards was 
assessed randomly by injecting replicate freshly prepared 
samples in autosampler after the initial injection. The 
peak areas of the analytes and internal standard obtained 
at initial run were marked as the reference to assess the 
relative stability of the analytes at further stages. Stability 
of analytes for benchtop study is performed at two different 
concentrations in six replicates. Freezer stability of the 
analytes for the biosamples was assessed by analyzing 
the QC samples stored at –70 °C±15°C. The stability 
of analytes in biomatrix following repeated freeze-thaw 
cycles (stored at –70 °C±15 °C between cycles) was 
assessed using QC samples spiked with analytes. Samples 
were considered to be stable if assay values were within 
the acceptable limits of accuracy (i.e., ±15% SD) and 
precision (i.e., 15% RSD). 
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RESULTS 
Liquid chromatography and mass spectroscopy 
Method development using various solvents such 
as acetonitrile and methanol, using different buffers such 
as ammonium formate, ammonium acetate and formic 
acid; changed flow-rates (0.1-1.5 mL/min) were tried 
for effective separation of analytes with good resolution. 
Finally, the desired resolution was accomplished with 
5mM ammonium acetate: acetonitrile (25:75, v/v) at a flow 
rate of 1.0 mL/min, on Zorbax Eclipse XBD C18 (150 × 
4.6 mm, 5 µm) column for the evaluation of electrospray 
response for CAN, HCT, CAN-IS and HCT-IS. In order to 
finalize ESI conditions for CAN, HCT, CAN-IS and HCT-
IS, the assessment was carried out in negative ionization 
mode with MRM scan. The mass spectra for CAN, HCT, 
CAN-IS and HCT-IS observed peaks at m/z 439.00, 
295.80, 443.00, and 301.80 respectively. The transition of 
m/z 439.00 → 309.10 was used for quantification of CAN 
and m/z 295.80 → 268.80 was used for quantification of 
HCT. Similarly, for CAN-IS m/z 443.00 → 312.00 and 
m/z 301.80 → m/z 274.90 was used for quantification of 
HCT-IS was used for assessment purpose. Mass tuning 
peaks are depicted in Figures 1 and 2.
The ideal combination of Zorbax Eclipse column 
usage and negative ion mode for quantification of CAN and 
HCT helped in achieving greater resolution of the peaks 
and also for concurrent quantification of both analytes with 
low LLOQ and shorter run time compared with the earlier 
reported independent methods. Moreover, the employment 
of isotopic internal standards helped in achieving recovery 
values on the higher end compared to previous methods.
Matrix effect, specificity and sensitivity 
Interferences were not observed at the retention 
times of the analytes when the blank plasma samples 
FIGURE 1 - Mass tuning peaks of candesartan & candesartan D4.
FIGURE 2 - Mass tuning peaks of hydrochlorothiazide & hydrochlorothiazide 13C6
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from different lots were injected into the system. Under 
sensitivity studies, the %CV value was found to be 6.53 
which is acceptable as per the guidelines. The average 
matrix factor values calculated are 1.060 for CAN and 
1.033 for HCTZ at LLOQ QC and HQC concentrations. 
Significant peaks were absent at the retention times of 
analytes and no change in peak areas of the analytes was 
observed which indicates very less effect of plasma extract 
on the ionization of analytes and internal standards.
A representative chromatogram for the control 
human plasma (free of the analyte and IS) and human 
plasma spiked with CAN, HCT, CAN-IS, HCT-IS at 
LLOQ are shown in Figure 3 to Figure 8 respectively. No 
interfering peaks from interfering compounds are observed 
at the retention times of analytes and IS. The retention time 
of CAN and CAN-IS was 1.10 min and HCT and HCT-IS 
was 1.40 min. respectively. The total chromatographic run 
time was 3.0 min.
Recovery 
Recovery was evaluated for each analyte at HQC 
concentration and the response in terms of peak area was 
employed for the calculations. Recovery was found to be 
to be 98.86%±1.17% and 99.72%±1.40% for CAN and 
HCT respectively. The recovery of CAN-IS and HCT-IS 
was 96.95%±3.69% and 100.55% ±2.10%. The results 
obtained in recovery studies were tabulated in Table III.
FIGURE 4 - Representative chromatogram of blank plasma sample-HCT.
FIGURE 5 - Representative chromatogram of blank plasma sample with CAN- IS.
FIGURE 3 - Representative chromatogram of blank plasma sample-CAN.
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Calibration curve 
The calibration curve plotted shows outstanding 
recovery in the entire calibration range. The plot was 
drawn by taking peak-area ratios (peak area analyte/peak 
area IS) on x-axis and concentration on y-axis considering 
their best fit using weighing factor (1/x2). The mean 
regression (n=4) was found to be >0.995. The lowest 
concentration with the RSD<20% was taken as LLOQ 
and was found to be 1.080 and 1.092 ng/mL for CAN 
and HCT respectively. The %accuracy calculated for the 
mean of back-calculated concentrations for five calibration 
curves for CAN and HCT was within 97.54-99.78 and 
97.39-100.67, respectively; while the precision (%CV) 
values diverse from 7.06-7.02 and 1.49-4.39 for CAN and 
HCT, respectively. 
FIGURE 6 - Representative chromatogram of blank plasma sample with HCT-IS.
FIGURE 7 - Representative chromatogram of standard CAN (LLOQ sample).
FIGURE 8 - Representative chromatogram of standard HCT (LLOQ sample).
TABLE III - Recovery and matrix effect of CAN and HCT QC 
samples
Analyte ID
QC sample 
(ng/mL) 
n=6
% Recovery
IS normalized 
matrix factor
CAN LQC 3.087 99.78±7.06 1.060±6.12
MQC 152.516 99.26±2.01 -------
HQC 256.523 95.54±3.41 0.985±1.26
CAN-IS ---- 250 96.95±3.69 -------
HCT LQC 3.121 98.31±3.92 1.033±5.98
MQC 154.199 101.11±2.24 -------
HQC 261.354 99.73±3.21 1.015±0.86
HCT-IS ---- 250 100.55±2.19 -------
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Accuracy and precision 
Accuracy and precision data for intra-day and inter-
day plasma samples for CAN and HCT are presented in 
Table IV. The assay values on both the occasions (intra and 
inter-day) were found to be within the accepted variable 
limits. 
Stability 
The selected concentrations for CAN and HCT 
at LQC and HQC deviated within ±15% of the average 
concentrations in a series of stability tests viz., 53.00 h 
(in-injector), 15.00 h (bench-top), and for 112 days freezer 
stability at –70 °C±15 °C (Table V). 
DISCUSSION
Several methods have been reported for the 
estimation of CAN and HCT using LC-MS/MS. Till date, 
no LC-MS/MS method was reported for the simultaneous 
determination of these drugs using isotopic internal 
standards. It is always recommended to select an internal 
standard with close chemical properties to have effective 
extraction and recovery values. Bearing this fact in mind, 
we have selected isotopic internal standards for both the 
drugs. In addition, the earlier reported methods have got 
fewer recovery values due to the employment of regular 
extraction procedures. 
I t  w a s  i n d e e d  a n  e s s e n c e  i n  o p t i m i z i n g 
chromatographic conditions, mass spectrometric 
parameters and extraction techniques to develop 
a selective, sensitive and rapid assay method for 
simultaneous determination of CAN and HCT in human 
plasma. Under mentioned conditions, CAN, HCT, CAN-
IS and HCT-IS exhibit a high sensitivity in negative 
ion detection mode rather than positive ion detection 
mode. The final composition of mobile phase was 5mM 
ammonium acetate: acetonitrile (25:75, v/v), both analytes 
and their internal standards got good responses with the 
possible best peaks and eluted within 3 minutes. The 
method got all the validation parameters in limits and has 
got greater recovery values compared to earlier reported 
methods.
CONCLUSION 
A highly sensitive, specific, reproducible and 
high-throughput LC- MS/MS bioanalytical method was 
developed and validated to quantify CAN and HCT 
simultaneously in human plasma. This method could 
be used to characterize the concentrations of CAN and 
HCT in pharmacokinetic studies. We believe that the 
LC-MS/MS method presented by us has got good merits 
over the earlier reported methods. Advantages of the 
current method is less sample volume, utilizes simple 
extraction method and enables simultaneous estimation 
of combination drugs; hence we believe that the future 
TABLE IV - Intra and inter-day precision of CAN and HCT QC samples
Measured concentration (ng/mL)
Intra-day variation (Six replicates at each concentration)
Theoretical 
Concentration (nm/mL)
CAN HCT
Mean SD % CV Accuracy (%) Mean SD % CV Accuracy (%)
LLOQ 1.02 0.05 4.72 94.17 1.06 0.06 6.30 97.12
LQC 3.05 0.29 9.62 98.90 3.19 0.17 5.46 102.50
MQC1 35.17 1.76 5.01 100.26 36.92 1.72 4.67 104.10
MQC2 154.47 5.51 3.56 101.28 159.00 4.79 3.02 103.12
HQC 256.20 17.51 6.84 99.11 262.07 7.64 2.92 100.28
Inter-day variation (Thirty replicates at each concentration)
LLOQ 1.05 0.07 6.94 97.17 1.08 0.09 8.00 98.79
LQC 3.10 0.24 7.75 100.45 3.14 0.15 4.79 100.76
MQC1 34.80 1.51 4.34 99.20 36.00 1.44 4.02 101.50
MQC2 154.89 5.20 3.36 101.56 156.97 4.25 2.71 101.80
HQC 257.56 12.11 4.71 99.64 262.40 5.61 2.14 100.40
RSD: Relative standard deviation (SD X 100/Mean)
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TABLE V - Stability data of CAN and HCT quality controls in human plasma
Drug Nominal conc. (ng/mL) Stability
Mean ± SDa 
(n=6) 
(ng/mL)
Accuracy (%)b Precision(%) % C.V.
CAN 
LQC
3.087 0 h (for all) 2.85 91.78 4.51
3.087 15 h (bench-top) 3.07 99.67 3.49
3.087 53.00 h (in injector) 2.86 92.84 2.24
3.087 112 days at -70±5 ˚C 3.03 98.42 6.12
3.087 Freeze-thaw stability 
(5 cycles at-70±5 ˚C)
3.00 97.21 3.32
HCT 
LQC
3.121 0 h (for all) 3.03 98.12 3.12
3.121 15 h (bench-top) 2.92 93.65 4.10
3.121 53.00 h (in injector) 3.27 104.92 8.23
3.121 112 days at -70±5 ˚C 3.13 100.48 7.75
3.121 Freeze-thaw stability 
(5 cycles at-70±15 ˚C)
3.08 98.81 4.12
CAN 
HQC
258.502 0 h (for all) 264.20 101.57 2.91
258.502 15 h (bench-top) 272.53 105.43 1.78
258.502 53.00 h (in injector) 254.67 98.52 1.76
258.502 112 days at -70±15 ˚C 259.08 100.22 2.39
258.502 Freeze-thaw stability 
(5 cycles at-70±15 ˚C)
258.57 100.03 3.84
HCT 
HQC
261.354 0 h (for all) 256.04 98.88 1.52
261.354 15 h (bench-top) 255.75 97.85 1.72
261.354 53.00 h (in injector) 270.92 103.66 6.36
261.354 112 days at -70±15 ˚C 265.69 101.66 4.77
261.354 Freeze-thaw stability 
(5 cycles at-70±15 ˚C)
268.33 102.67 4.92
aBack-calculated plasma concentration; b(Mean assayed conc. At 0 h) X 100
bioanalytical methods would utilize this method for 
estimation of CAN and HCT in various biological matrices 
with little or no modification. 
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